NEWS

News Articles

Gwinnett Chamber Announces New President & CEO

April 12, 2019

The Gwinnett Chamber, one of the largest suburban Chambers of Commerce in the nation, recently announced its selection for its new President & CEO, effective July 1. Following a four-month search process, members of the Gwinnett Chamber board of directors voted in support of appointing Nick Masino, currently Gwinnett Chamber & Partnership Gwinnett’s Chief Economic…

Read More

House Bill Targets Looming $20 Billion Tax On MedTech Industry

April 10, 2019

April 10, 2019. WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation (H.R. 2207) in the U.S. House of Representatives to permanently repeal the medical device excise tax: “America’s medical technology industry is facing a $20 billion tax increase at year-end,…

Read More

Georgia Bio Names Westminster School Junior as Georgia BioGENEius Winner

April 10, 2019

Ananya Ganesh Advances to Philadelphia in International Competition Against Top Students  Atlanta, GA (April 10, 2019)– Georgia Bio and the Georgia BioEd Institute today named Ananya Ganesh, a junior at The Westminster Schools in Atlanta, GA, as the winner of the 2019 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding…

Read More

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

April 9, 2019

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1)EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2)EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)   THOUSAND OAKS, Calif. and BRUSSELS, April…

Read More

Alpharetta biopharma company names board member as interim CEO

April 8, 2019

An Alpharetta company that is working on treatments for eye disease patients has named a member of its board of directors as interim CEO. George Lasezkay succeeds Daniel H. White as chief executive of Clearside Biomedical Inc. (NASDAQ: CLSD). White resigned as president, CEO and as a member of the Clearside board to pursue other…

Read More